BROADWOOD CAPITAL INC - Q4 2020 holdings

$1.69 Billion is the total value of BROADWOOD CAPITAL INC's 8 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 14.3% .

 Value Shares↓ Weighting
STAA  STAAR SURGICAL CO$855,207,000
+40.1%
10,795,3480.0%50.73%
+5.7%
MNST  MONSTER BEVERAGE CORP NEW$430,632,000
+15.3%
4,656,4880.0%25.54%
-13.0%
IWM SellISHARES TRrussell 2000 etf$197,962,000
+20.7%
1,009,700
-7.8%
11.74%
-8.9%
AXON  AXON ENTERPRISE INC$93,130,000
+35.1%
760,0620.0%5.52%
+1.9%
LCTX  LINEAGE CELL THERAPEUTICS IN$59,849,000
+87.9%
34,005,3790.0%3.55%
+41.8%
OCX  ONCOCYTE CORP$35,172,000
+71.9%
14,716,2040.0%2.09%
+29.6%
MNST NewMONSTER BEVERAGE CORP NEWput$9,248,000100,000
+100.0%
0.55%
AGE  AGEX THERAPEUTICS INC$4,556,000
+87.6%
2,997,1560.0%0.27%
+41.4%
Other managers

Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):

Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2021-02-16
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
STAAR SURGICAL CO42Q3 202359.1%
MONSTER BEVERAGE CORP NEW34Q3 202349.7%
ISHARES TR33Q3 202314.8%
ONCOCYTE CORPORATION31Q2 20234.6%
BIOTIME INC25Q2 201917.8%
AXON ENTERPRISE INC24Q3 202313.4%
AGEX THERAPEUTICS INC20Q3 20231.5%
LINEAGE CELL THERAPEUTICS INC17Q3 20235.1%
ASTERIAS BIOTHERAPEUTICS INC16Q4 20182.9%
CYNOSURE INC15Q4 201610.4%

View BROADWOOD CAPITAL INC's complete holdings history.

Latest filings
TypeFiled
42024-04-15
13F-HR2024-02-14
42024-02-08
42024-01-10
42024-01-05
42023-11-30
13F-HR2023-11-14
42023-11-14
42023-11-09
42023-11-06

View BROADWOOD CAPITAL INC's complete filings history.

Compare quarters

Export BROADWOOD CAPITAL INC's holdings